Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) saw strong trading volume on Monday . 1,789,449 shares changed hands during trading, a decline of 33% from the previous session's volume of 2,676,402 shares.The stock last traded at $4.43 and had previously closed at $4.31.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently commented on the company. Leerink Partners increased their price target on Xeris Biopharma from $5.00 to $6.00 and gave the stock an "outperform" rating in a research report on Friday, March 7th. Jefferies Financial Group reiterated a "buy" rating and issued a $6.00 price target (up from $4.00) on shares of Xeris Biopharma in a research report on Wednesday, January 29th. Piper Sandler reaffirmed a "neutral" rating and issued a $4.00 target price (up previously from $3.00) on shares of Xeris Biopharma in a research note on Friday, March 7th. Craig Hallum upped their price objective on shares of Xeris Biopharma from $5.00 to $6.50 and gave the company a "buy" rating in a research report on Friday, March 7th. Finally, HC Wainwright reiterated a "buy" rating and set a $8.00 target price (up from $6.60) on shares of Xeris Biopharma in a report on Friday, March 7th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $6.10.
Read Our Latest Stock Report on XERS
Xeris Biopharma Stock Up 0.3 %
The company has a market capitalization of $665.79 million, a P/E ratio of -9.61 and a beta of 1.37. The business has a fifty day moving average price of $4.50 and a 200 day moving average price of $3.75.
Insiders Place Their Bets
In related news, insider Beth Hecht sold 40,000 shares of the company's stock in a transaction dated Thursday, March 20th. The stock was sold at an average price of $5.43, for a total transaction of $217,200.00. Following the sale, the insider now owns 1,353,510 shares in the company, valued at approximately $7,349,559.30. This represents a 2.87 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 4.56% of the company's stock.
Institutional Investors Weigh In On Xeris Biopharma
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Legato Capital Management LLC bought a new stake in Xeris Biopharma during the fourth quarter worth $482,000. Barclays PLC increased its stake in shares of Xeris Biopharma by 87.8% during the 3rd quarter. Barclays PLC now owns 324,472 shares of the company's stock worth $925,000 after purchasing an additional 151,685 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Xeris Biopharma by 2.9% in the 3rd quarter. Geode Capital Management LLC now owns 3,333,470 shares of the company's stock valued at $9,502,000 after purchasing an additional 93,091 shares during the period. Connor Clark & Lunn Investment Management Ltd. grew its holdings in Xeris Biopharma by 106.2% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 171,332 shares of the company's stock worth $581,000 after purchasing an additional 88,224 shares during the period. Finally, Principal Financial Group Inc. increased its position in Xeris Biopharma by 30.3% during the third quarter. Principal Financial Group Inc. now owns 102,469 shares of the company's stock worth $292,000 after buying an additional 23,843 shares during the last quarter. Institutional investors own 42.75% of the company's stock.
About Xeris Biopharma
(
Get Free Report)
Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Xeris Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xeris Biopharma wasn't on the list.
While Xeris Biopharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
